Evidence map›Paper›PMID 41369198›Full record

ArticlemBio2026

The pandemic gap of respiratory viruses during the COVID-19 pandemic.

Viviana Simon, Daniel Floda, Charles Gleason, Ana Silvia Gonzalez-Reiche, Alberto E Paniz-Mondolfi, Emilia Mia Sordillo, Peter Palese, Harm van Bakel

Abstract read
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Assessing COVID-19 Testing Strategies in K-12 Schools in Underserved Populations.Journal of public health management and practice : JPHMP
    Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-6416-5096
Daniel FlodaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Charles GleasonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ana Silvia Gonzalez-ReicheDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-3583-4497
Alberto E Paniz-MondolfiDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-1259-1736
Emilia Mia SordilloDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-7787-3051
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-0337-5823
Harm van BakelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-1376-6916

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES75N93023C00019 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2023 to 2023
$15.9M
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infectionR01AI145870 · NIAID · ROCKEFELLER UNIVERSITY · PI Peter Palese, JEFFREY Victor RAVETCH · 2019 to 2026
$8.4M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93023C00019NIAID NIH HHS R01 AI145870
6 · The paper itself

Abstract

Respiratory viruses typically exhibit seasonal patterns, posing ongoing public health challenges. The coronavirus disease 2019 pandemic altered these patterns dramatically, with many common respiratory viruses disappearing from circulation for extended periods. Here we analyzed over three million diagnostic tests from a metropolitan healthcare system in New York City over 7 years, tracking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and eight common respiratory viruses before and during the pandemic. Following the initial SARS-CoV-2 wave in the spring of 2020, influenza A/B, respiratory syncytial virus, seasonal coronaviruses, parainfluenza, and human metapneumoviruses were absent for months to years, a phenomenon that we termed the "pandemic gap." This disruption likely resulted from public health measures and SARS-CoV-2-induced antiviral immune responses resembling trained immunity. These findings suggest that the pandemic has temporarily reshaped respiratory virus epidemiology, potentially affecting immune development and increasing susceptibility to future respiratory virus epidemics. IMPORTANCE: In this retrospective study using millions of diagnostic tests over 7 years from patients at the Mount Sinai Health System in New York City, we show that when the coronavirus disease 2019 pandemic began in early 2020, many but not all common respiratory viruses disappeared from circulation. We observed prolonged absences ranging from 10 months to nearly 3 years for viruses such as influenza A/B viruses, respiratory syncytial viruses, seasonal coronaviruses, parainfluenza, and human metapneumoviruses. This unusual decline in enveloped respiratory RNA virus activities may have been linked to public health interventions like social distancing, wearing of masks, and lockdowns. Additionally, the rapid spread of severe acute respiratory syndrome coronavirus 2 may have triggered broad, pathogen-agnostic immune responses and the imprinting of antiviral signatures in innate immune cells that conferred temporary protection against other viruses. This phenomenon resembles "trained immunity," a form of enhanced innate immune memory observed after certain infections or vaccinations.

Indexed as

COVID-19PandemicsRespiratory Tract InfectionsHumansNew York CityRetrospective StudiesSARS-CoV-2Seasonsepidemiologyinfluenza virusesrespiratory virusesSARS-CoV-2surveillance

Identifiers

PMID41369198
PMCPMC12802283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.